Breakthrough CNS Treatments Will Reshape Neurodegenerative Care

Published
03 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$4.51
51.2% undervalued intrinsic discount
15 Aug
US$2.20
Loading
1Y
-58.4%
7D
0.9%

Author's Valuation

US$4.5

51.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on15 Aug 25

With no change in the discount rate or net profit margin, Alector’s consensus analyst price target remained stable at $4.51. What's in the News Alector updated its 2025 collaboration revenue guidance to $13 million–$18 million.

Shared on01 May 25
Fair value Increased 24%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 23%

AnalystConsensusTarget has decreased revenue growth from 38.2% to -15.7%, increased profit margin from 0.4% to 17.3% and decreased future PE multiple from 619.7x to 53.1x.

Shared on09 Apr 25
Fair value Increased 13%